Download this slideset to gain key insights on adjuvant therapy and best practice management of high-risk melanoma through the use of targeted therapy and immunotherapy
Download this slideset to gain key insights into current therapeutic strategies in advanced melanoma, including optimal approaches for managing CNS metastases.
Download this short summary slideset of key takeaways from a live CCO Webinar focused on current management of patients with high-risk resectable or metastatic melanoma.
How do you choose among approved adjuvant therapies for BRAF V600E/K high-risk melanoma? Read my thoughts on factors to consider when selecting adjuvant targeted therapy for your patients.
Here are my thoughts on key considerations when selecting frontline therapy for patients with metastatic melanoma, including when targeted therapy may be preferred over immunotherapy, factors that affect the selection of single-agent or combination immunotherapy, and when to discontinue immunotherapy.
Experts answer frequently asked questions on the management of melanoma, including adjuvant therapy selection, considerations for frontline treatment, and biomarker testing.
In this engaging and concise interactive module, gain insights on empowering patients with melanoma to be a central figure in their own care before, during, and after treatment.
In this engaging and concise interactive virtual presentation, learn how melanoma experts utilize biomarkers such as BRAF, NRAS, c-KIT, and PD-L1, to inform treatment decisions.
In this concise interactive module, learn from experts about emerging therapeutic regimens for advanced melanoma, including tumor-infiltrating lymphocytes, intratumorally administered agents, and targeted therapy combinations.
In this concise interactive module, learn how melanoma experts apply current treatment algorithms in multiple settings, including adjuvant therapy and unresectable or metastatic disease.